Testing petrelintide for weight loss in people with type 2 diabetes
Compares a new weekly medicine with placebo in adults with excess weight and diabetes.
Plain-language title generated from the registry record
Registry title: A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes
Key facts
- Where
- Los Angeles and Manassas, United StatesSee the 2 sites
- Phase
- Phase 3
Where in United States
- Institute for Metabolic Research Los AngelesLos Angeles, United StatesTaking people
- Manassas Clinical Research CenterManassas, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hoffmann-La Roche
- Trial code
- NCT07843485EU 2026-526189-25-00
- Record updated
- 5 November 2026
- Original description
This study will evaluate the efficacy and safety of petrelintide compared with placebo, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or obesity and with Type 2 Diabetes (T2D).Read full original descriptionShow less
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once Weekly Petrelintide vs. Placebo in Participants With Overweight or Obesity and Type 2 Diabetes
This study will evaluate the efficacy and safety of petrelintide compared with placebo, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or obesity and with Type 2 Diabetes (T2D).
Inclusion: Participants with BMI ≥ 27 kg/m²; T2D diagnosis as per World Health Organization (WHO) classification (or other locally applicable standards) with HbA1c ≥ 6.5% to ≤ 10% (48-86 mmol/mol), measured by the central laboratory at screening; Stable treatment with either diet and exercise alone, basal insulin, or selected oral glucose-lowering agents, for at least 90 days prior to and during screening; History of at least one self-reported unsuccessful dietary effort to lose body weight.
Exclusion: Current or previous treatment with petrelintide or any other amylin analog; History or presence of proliferative diabetic retinopathy, or diabetic macular edema.